Results 31 to 40 of about 7,984 (250)

Insulin Antibody-induced Diabetic Ketoacidosis in an Elderly Type 2 Diabetic Ameliorated with Prednisolone [PDF]

Journal of Clinical and Diagnostic Research, 2018
In the patients who are treated with insulin, the synthesis of insulin antibodies occasionally induce difficulty in glycaemic management. Insulin antibodies are now being closely examined in the context of diabetes treatment.
Yuko Matsumoto, Hodaka Yamada, Masafumi Kakei, San E Ishikawa, Kazuo Hara   +4 more
doaj   +1 more source

Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes

Therapeutic Advances in Endocrinology and Metabolism, 2012
The three currently marketed long-acting insulin analogs, glargine, detemir and insulin lispro protamine suspension (ILPS), represent the most significant advances in basal insulin supplementation since the 1940s and 1950s and the introduction of the ...
Dario Giugliano, Katherine Esposito
doaj   +1 more source

Managing feline diabetes: current perspectives [PDF]

, 2018
Diabetes mellitus is a common endocrine disease in cats. While type 2 diabetes is the most common form seen in cats, other underlying causes may contribute to insulin resistance.
Gottlieb, Susan, Rand, Jacquie
core   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Characterisation of insulin analogues therapeutically available to patients [PDF]

, 2018
The structure and function of clinical dosage insulin and its analogues were assessed. This included ‘native insulins’ (human recombinant, bovine, porcine), ‘fast-acting analogues’ (aspart, glulisine, lispro) and ‘slow-acting analogues’ (glargine ...
Adams, Gary G., Alzahrani, Qushmua E., Ballance, Simon, Besong, David T.M., Chayen, Naomi, Gillis, Richard B., Harding, Stephen E., Jiwani, Shahwar I., Kok, M. Samil, Lithgo, Ryan, Meal, Andrew, Morgan, Paul S., Zobel, Hanne   +12 more
core   +5 more sources

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Diabetes, Metabolic Syndrome and Obesity, 2010
Jean-Pierre Le FlochDepartment of Diabetology, Medical Clinic, Villecresnes, FranceAbstract: Insulin detemir is an analog of human insulin designed to provide a long duration of basal insulin action.
Jean-Pierre Le Floch
doaj   +2 more sources

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Henry Y. Han, Martin Pfohl, Jochen Seufert   +6 more
wiley   +1 more source

Pediatric Obesity: Influence on Drug Dosing and Therapeutics [PDF]

, 2018
Obesity is an ongoing global health concern and has only recently been recognized as a chronic disease of energy homeostasis and fuel partitioning. Obesity afflicts 17% of US children and adolescents.
Ameer, Barbara, PharmD, MBA, BCPS, FCP, Weintraub, Michael, MD   +1 more
core   +1 more source